AxoGen(US:AXGN)2025-08-05 12:00Financial Performance - Q2 2025 revenue increased to $56.7 million, representing an 18.3% year-over-year growth[12,22] - Q2 2025 gross margin was 74.2%, a 0.4% increase compared to 2024[24] - Net income for Q2 2025 was $0.6 million, compared to a loss of $1.9 million in Q2 2024[26] - Adjusted EBITDA for Q2 2025 was $9.3 million, compared to $5.6 million in Q2 2024[26] - Operational cash flow increased by $7.8 million, from $28.1 million on March 31, 2025, to $35.9 million on June 30, 2025[28] Business Growth & Development - High Potential (HiPo) accounts yielded approximately 70% of year-over-year revenue growth year-to-date[12] - HiPo accounts have yielded a 21% year-over-year increase in average account productivity year-to-date[12] - The company added approximately 10 million estimated additional covered lives in Q2 via BCBS policy changes, with approximately 17 million estimated new lives year-to-date[14] Guidance - The company raised its full-year 2025 revenue growth guidance to at least 17%, or $219 million[30]